Green Cross Corporation - Product Pipeline Review - 2014
Summary
Global Markets Direct’s, ‘Green Cross Corporation - Product Pipeline Review - 2014’, provides an overview of the Green Cross Corporation’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Green Cross Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Green Cross Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Green Cross Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Green Cross Corporation’s pipeline products
Reasons to buy
- Evaluate Green Cross Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Green Cross Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Green Cross Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Green Cross Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Green Cross Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Green Cross Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Green Cross Corporation Snapshot 6
Green Cross Corporation Overview 6
Key Information 6
Key Facts 6
Green Cross Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Green Cross Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Green Cross Corporation - Pipeline Products Glance 14
Green Cross Corporation - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Green Cross Corporation - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Green Cross Corporation - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Green Cross Corporation - Drug Profiles 18
coagulation factor VIII (recombinant) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
GC-1107 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
GC-1112 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GC-3102C 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GC-3110A 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
immune globulin (human) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MG-1109 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GC-1102 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GC-1109 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
idursulfase 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GC-3106A 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GCC-2107 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
margetuximab 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MG-1102 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MG-4101 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GC-1118A 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GC-3111A 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MG-1111 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody Conjugate to Target Her2 for Breast Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rituximab biosimilar 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Green Cross Corporation - Pipeline Analysis 41
Green Cross Corporation - Pipeline Products by Target 41
Green Cross Corporation - Pipeline Products by Route of Administration 43
Green Cross Corporation - Pipeline Products by Molecule Type 44
Green Cross Corporation - Pipeline Products by Mechanism of Action 45
Green Cross Corporation - Recent Pipeline Updates 46
Green Cross Corporation - Dormant Projects 49
Green Cross Corporation - Company Statement 50
Green Cross Corporation - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List Of Tables
List of Tables
Green Cross Corporation, Key Information 6
Green Cross Corporation, Key Facts 6
Green Cross Corporation - Pipeline by Indication, 2014 9
Green Cross Corporation - Pipeline by Stage of Development, 2014 10
Green Cross Corporation - Monotherapy Products in Pipeline, 2014 11
Green Cross Corporation - Partnered Products in Pipeline, 2014 12
Green Cross Corporation - Partnered Products/ Combination Treatment Modalities, 2014 13
Green Cross Corporation - Phase III, 2014 14
Green Cross Corporation - Phase II, 2014 15
Green Cross Corporation - Phase I, 2014 16
Green Cross Corporation - Preclinical, 2014 17
Green Cross Corporation - Pipeline by Target, 2014 42
Green Cross Corporation - Pipeline by Route of Administration, 2014 43
Green Cross Corporation - Pipeline by Molecule Type, 2014 44
Green Cross Corporation - Pipeline Products by Mechanism of Action, 2014 45
Green Cross Corporation - Recent Pipeline Updates, 2014 46
Green Cross Corporation - Dormant Developmental Projects,2014 49
Green Cross Corporation, Other Locations 51
Green Cross Corporation, Subsidiaries 52
List Of Figures
List of Figures
Green Cross Corporation - Pipeline by Top 10 Indication, 2014 8
Green Cross Corporation - Pipeline by Stage of Development, 2014 10
Green Cross Corporation - Monotherapy Products in Pipeline, 2014 11
Green Cross Corporation - Partnered Products in Pipeline, 2014 12
Green Cross Corporation - Pipeline by Top 10 Target, 2014 41
Green Cross Corporation - Pipeline by Top 10 Route of Administration, 2014 43
Green Cross Corporation - Pipeline by Top 10 Molecule Type, 2014 44
Green Cross Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014 45
